Research on Glioblastomas Reported by Researchers at Children's Hospital of Nanjing Medical University (The Prognostic Effect of Dexamethasone on Patients With Glioblastoma: A Systematic Review and Meta-Analysis)

摘要

2021 SEP 17 (NewsRx) - By a News Reporter-Staff News Editor at Disease Prevention Daily - Fresh data on glioblastomas are presented in a new report. According to news reporting out of Nanjing, People's Republic of China, by NewsRx editors, research stated, "Dexamethasone (DEX) is widely adopted to reduce tumor-associated edema in glioblastoma (GBM) patients despite its side effects. However, the benefits of using DEX in GBM patients remains elusive." The news editors obtained a quote from the research from Children's Hospital of Nanjing Medical University: "In this study, we performed a comprehensive meta-analysis to address this concern. We searched the relevant studies from PubMed, Web of Science, and EMBASE databases, and then applied random or fixed-effects models to generate estimated summary hazard radios (HRs) and the 95% confidence intervals (CIs). Moreover, subgroup and sensitivity analysis were conducted and publication bias were further evaluated. Ten articles with a total of 2,230 GBM patients were eligible according to the inclusion criteria. In the assessment of overall survival (OS), meta-analysis data revealed that DEX was significantly associated with the poor prognosis of GBM patients (HR=1.44, 95% Cl=1.32-1.57).